Cell viability and activity testing for organ repair is a critical quality control and safety evaluation step for stem cell therapies, tissue-engineered constructs, organoids, and ex vivo perfused organs. This technical article explains the key sample types, testing parameters, analytical methods, applicable international standards, and typical applications involved in assessing the functional integrity of cells used in organ regeneration. Testing of this kind is routinely performed by accredited third-party laboratories in accordance with ISO, ASTM, and GB standards.
Technical Overview
Cell viability and activity testing for organ repair refers to the systematic evaluation of the survival status, metabolic function, proliferative capacity, and biological potency of living cells intended to restore, support, or regenerate damaged organ tissue. These cells may be administered as therapeutic suspensions, seeded onto scaffolds, incorporated into three-dimensional (3D) bioprinted or organoid constructs, or evaluated within whole organs maintained on ex vivo perfusion systems. Because the therapeutic effect of any organ repair product depends directly on the proportion of functional, metabolically active cells, quantitative viability and activity data are required for batch release, process validation, stability studies, and regulatory submissions.
A comprehensive testing program combines complementary readouts: membrane integrity assays confirm whether cells are structurally intact, metabolic assays reveal whether intact cells are biochemically active, proliferation and apoptosis assays describe population dynamics, and potency-oriented assays demonstrate that cells retain organ-relevant functions, such as albumin secretion for hepatocyte-like cells or contractile behavior for cardiomyocyte products. Testing is commonly performed under ISO/IEC 17025-accredited conditions, with method selection guided by ISO 10993 for the biological evaluation of medical devices, the corresponding Chinese standard series GB/T 16886, and ASTM guides such as ASTM F2150 and ASTM F2739.
Testing Samples
Stem Cell and Cell Therapy Products
Therapeutic cell suspensions are the most common sample type, including mesenchymal stromal cells (MSCs), induced pluripotent stem cell (iPSC) derivatives, hematopoietic cells, hepatocyte-like cells, and cardiomyocyte-like cells. Samples may be submitted fresh or cryopreserved, and post-thaw recovery assessment is typically required for cryopreserved lots. Submissions should include cell type, passage number, concentration, excipient composition, and requested release specifications.
Cell-Seeded Scaffolds and Tissue-Engineered Constructs
Cells cultured on decellularized extracellular matrix, hydrogels, biodegradable polymer scaffolds, or 3D bioprinted structures require specialized testing that evaluates seeding efficiency, spatial distribution, penetration depth into the matrix, and viability retention over the culture period. Both the cellular component and the scaffold material itself may be subjects of evaluation.
Organoids and Microphysiological Systems
Liver, kidney, intestinal, and cardiac organoids, as well as organ-on-chip models, are tested for viability in combination with organ-specific functional endpoints. This ensures that the model remains physiologically relevant for downstream drug screening or mechanistic studies.
Ex Vivo Perfused Organs and Perfusate Samples
Organs maintained under hypothermic or normothermic machine perfusion prior to transplantation are monitored through serial perfusate samples and wedge biopsies. Perfusion fluid biomarkers such as lactate, pH, glucose, and organ-specific enzymes provide real-time indicators of cellular activity and metabolic commitment.
Decellularized Scaffolds and Repair Biomaterials
For decellularized tissues and organ-derived matrices, testing verifies the completeness of cell removal, quantifies residual DNA, and confirms that material extracts do not impair the viability of recipient cells that will repopulate the scaffold, in line with ISO 10993-5 cytotoxicity principles.
Testing Items
Depending on the product type and stage of development, the following parameters are typically measured:
- Total cell count, viable cell count, and viability percentage
- Metabolic activity measured by MTT, WST-8, WST-1, resazurin, or ATP-based luminescent assays
- Lactate dehydrogenase (LDH) release as a marker of membrane damage and cytotoxicity
- Apoptosis, necrosis, and late-stage apoptosis distribution by flow cytometry
- Proliferation capacity, including EdU or BrdU incorporation, Ki-67 expression, and population doubling time
- Mitochondrial function, including membrane potential, oxygen consumption rate, and intracellular ATP
- Intracellular reactive oxygen species (ROS) and oxidative stress levels
- Senescence-associated markers such as SA-beta-galactosidase activity
- Clonogenic capacity, for example colony-forming unit-fibroblast (CFU-F) assays for MSCs
- Immunophenotypic identity and purity, for example CD73, CD90, and CD105 positivity with CD45, CD34, CD14, CD19, and HLA-DR negativity for MSCs
- Organ-specific functional potency markers, such as albumin and urea synthesis for hepatocyte products
- Spatial live/dead distribution and cell penetration depth within 3D constructs
- Residual DNA content and extract cytotoxicity for decellularized materials
Testing Methods
Membrane Integrity and Dye Exclusion Assays
Trypan blue exclusion combined with automated or manual cell counting provides the reference viable cell count required for dosing calculations. Propidium iodide (PI) and 7-aminoactinomycin D (7-AAD) are excluded by intact plasma membranes and are widely used as viability dyes in flow cytometry. Calcein-AM and PI double staining distinguishes live cells, which fluoresce green, from dead cells, which fluoresce red, and is suitable for both suspension and adherent cultures.
Metabolic and ATP-Based Activity Assays
Tetrazolium-based assays (MTT, WST-8, WST-1) and resazurin reduction assays quantify NAD(P)H-dependent intracellular dehydrogenase activity through colorimetric or fluorometric readouts. ATP-based luciferase luminescence assays provide a rapid and highly sensitive surrogate for cellular energy charge. Interpretation in 3D matrices requires care, because diffusion limitations and cell density can affect signal linearity, and standards such as ASTM F2739 provide guidance for quantifying viability within biomaterials.
Flow Cytometric Apoptosis and Viability Analysis
Annexin V combined with PI or 7-AAD enables four-quadrant discrimination of viable, early apoptotic, late apoptotic, and necrotic populations. Caspase-3/7 activity assays and TUNEL staining on tissue sections or biopsies provide complementary information on programmed cell death, particularly valuable for evaluating cells within native organ tissue or engineered constructs.
Mitochondrial and Energy Metabolism Profiling
JC-1 staining reports mitochondrial membrane potential, while extracellular flux analysis measures the oxygen consumption rate and extracellular acidification rate to characterize oxidative phosphorylation and glycolytic activity. ROS levels are commonly detected using DCFDA-based fluorescence. These assays are especially relevant for high-energy organs such as the heart and liver, where mitochondrial competence is a key determinant of repair efficacy.
Proliferation and Clonogenic Assays
EdU or BrdU incorporation and Ki-67 immunostaining quantify the fraction of cycling cells, while CFU-F assays measure the clonogenic potential of MSC populations. Population doubling time calculated over serial culture provides a longitudinal indicator of proliferative fitness and helps define cell banking strategies.
3D Construct, Scaffold, and Label-Free Techniques
Confocal z-stack imaging of optically cleared or sectioned constructs reveals the spatial distribution of live and dead cells throughout the matrix thickness. Enzymatic or chemical dissociation followed by flow cytometry or automated counting provides quantitative whole-construct data. Emerging label-free approaches, including Raman spectroscopy and impedance-based real-time cell analysis, allow non-destructive longitudinal monitoring of the same sample over time.
Ex Vivo Organ Viability Assessment
During machine perfusion, serial perfusate analysis tracks lactate clearance, pH stabilization, glucose utilization, oxygen consumption, and leakage of organ-specific enzymes. Biopsy histology, TUNEL staining, and mitochondrial activity measurements on perfused tissue support prediction of post-transplant organ function and inform acceptability decisions.
Cytotoxicity Testing Under ISO 10993-5
For scaffolds, hydrogels, and other biomaterials in contact with cells, extract-based assays are performed according to ISO 10993-5 and GB/T 16886.5, with sample preparation following ISO 10993-12. A material is generally considered to have no cytotoxic potential when cell viability remains at or above 70 percent of the negative control under the prescribed test conditions.
Applications
Cell viability and activity testing supports the entire development lifecycle of organ repair products, from early research to clinical deployment:
- Batch release quality control for therapeutic cell products intended for organ repair
- Biocompatibility and cytotoxicity evaluation of scaffolds, hydrogels, and implantable repair materials
- Process optimization of seeding density, culture duration, differentiation protocols, and cryopreservation parameters
- Post-thaw recovery and stability studies that support shelf-life definition and transport validation
- Real-time viability assessment of organs during ex vivo machine perfusion prior to transplantation
- Preclinical efficacy studies and regulatory submission support for regenerative medicine products
- Organoid-based drug screening, including hepatotoxicity and nephrotoxicity evaluation
FAQ
What is the difference between cell viability and cell activity?
Viability describes whether a cell is structurally alive, typically judged by an intact plasma membrane, while activity describes whether that cell is functionally engaged, reflected in metabolic rate, proliferation, secretion, or organ-specific performance. A population can be largely viable yet metabolically suppressed, so regulatory expectations increasingly emphasize potency assays that go beyond simple viability counting.
What viability threshold applies to therapeutic cell products?
Release specifications are product specific and defined by the manufacturer in consultation with regulatory authorities, but viabilities of at least 70 percent are a common minimum for many MSC-based products, with targets of 85 to 90 percent or higher typical for freshly processed material. For material-mediated cytotoxicity under ISO 10993-5 and GB/T 16886.5, 70 percent viability relative to the control is the recognized interpretation threshold.
How is viability measured inside thick 3D scaffolds?
Because light penetration is limited, laboratories use confocal imaging of cleared or sectioned constructs, enzymatic dissociation followed by flow cytometry or automated counting, histological assessment, and label-free optical or impedance methods. Each approach balances spatial information against quantitative throughput, and a combination of methods is often recommended for regulatory-grade characterization.
Which standards govern this type of testing?
The principal references include ISO 10993-5 and GB/T 16886.5 for cytotoxicity, ISO 10993-12 for sample preparation, ASTM F2150 for biomaterial scaffold characterization, ASTM F2739 for quantifying cell viability within biomaterials, and ISO/IEC 17025 for laboratory competence. ISO 20387 may additionally apply where biobanked specimens are involved.
How much sample is required and what is the turnaround time?
Most in vitro assays require approximately 100,000 to 1,000,000 cells per endpoint, with scaffold studies and ex vivo assessments quoted on a case-by-case basis. Routine viability and metabolic assays are typically completed within one to three working days, while clonogenic, potency, and differentiation-associated assays may require one to three weeks of culture.
Can cryopreserved cell products be tested for viability?
Yes, post-thaw viability testing is standard practice for cryopreserved products. Immediate assessment after thawing, combined with a recovery assessment after approximately 24 hours of culture, is recommended, since a subset of cells can lose membrane integrity or metabolic function with delayed onset after thawing.